OTCM
BINP
Market cap1mUSD
Jul 11, Last price
0.04USD
1D
0.00%
1Q
-48.00%
IPO
-98.14%
Name
Bionoid Pharma Inc
Chart & Performance
P/E
—
P/S
50.70
EPS
—
Div Yield, %
—
Shrs. gr., 5y
412.06%
Rev. gr., 5y
%
Revenues
38k
+4.06%
Net income
-8k
L
CFO
0k
P
Profile
Bionoid Pharma Inc. engages in the hemp cultivation business. The company is based in Beverly Hills, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | 38 4.06% | 36 -64.71% | |||
Cost of revenue | 29 | 19 | |||
Unusual Expense (Income) | |||||
NOPBT | 8 | 17 | |||
NOPBT Margin | 22.44% | 48.13% | |||
Operating Taxes | (8) | 2 | |||
Tax Rate | 0.01% | ||||
NOPAT | 16 | 17 | |||
Net income | (8) -628.08% | 1 -101.09% | |||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | |||||
BB yield | |||||
| Debt | |||||
Debt current | 155 | 155 | |||
Long-term debt | |||||
Deferred revenue | |||||
Other long-term liabilities | |||||
Net debt | 152 | 152 | |||
| Cash flow | |||||
Cash from operating activities | 230 | (21) | |||
CAPEX | |||||
Cash from investing activities | |||||
Cash from financing activities | (50) | ||||
FCF | 21 | (8) | |||
| Balance | |||||
Cash | 3 | 2 | |||
Long term investments | |||||
Excess cash | 811 | 653 | |||
Stockholders' equity | (19,263) | 1,388 | |||
Invested Capital | 19,334 | 78 | |||
ROIC | 0.17% | 25.29% | |||
ROCE | 11.88% | 22.06% | |||
| EV | |||||
Common stock shares outstanding | 53,995 | 53,995 | |||
Price | 1.00 -20.00% | 1.25 | |||
Market cap | 53,995 -20.00% | 67,493 | |||
EV | 54,147 | 67,646 | |||
EBITDA | 11 | 20 | |||
EV/EBITDA | 4,742.65 | 3,324.44 | |||
Interest | 481 | 380 | |||
Interest/NOPBT | 5.71% | 2.19% | |||